BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

OGN

Organon & Co.
NYSE · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$1.57B−1.7% year on year
$2B$1B$0
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 30 Oct 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

53.1%−1.9 pp year on year
65%60%55%50%
Q1 ’22Q2 ’23Q2 ’24Q3 ’25Q3 ’26
Company filings · 10-Q filed 30 Oct 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$1.46B+116.5% year on year
$1.5B$1B$500M$0
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 30 Oct 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$675M−13.1% year on year
$1B$500M$0
Q2 ’22Q2 ’23Q3 ’24Q3 ’25Q3 ’26
Company filings · 10-Q filed 30 Oct 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty